New cell therapy trial aims to tame eye inflammation
NCT ID NCT07427628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a one-time cell therapy called TRX103 for people with active non-infectious uveitis, a condition causing inflammation inside the eye. Up to 18 adults aged 18 to 70 will receive the treatment by IV and be monitored for a year. The main goal is to check safety and side effects, not yet to prove it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-INFECTIOUS UVEITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Byers Eye Institute
Palo Alto, California, 94303, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.